Human beta-defensin-3 promotes wound healing in infected diabetic wounds

Journal of Gene Medicine

Volumn 11, Issue 3, 2009, Pages 220-228

  Hirsch, Tobias ^a,b   Spielmann, Malte ^a,b   Zuhaili, Baraa ^a   Fossum, Magdalena ^a   Metzig, Marie ^a,b   Koehler, Till ^a   Steinau, Hans Ulrich ^b   Yao, Feng ^a   Onderdonk, Andrew Bruce ^a   Steinstraesser, Lars ^b   Eriksson, Elof ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Bacterial infection; Gene transfer; Host defense peptides; Innate immunity; S. aureus; Wound healing

Indexed keywords

ADENOVIRUS VECTOR; BETA DEFENSIN 3; BETA DEFENSIN; BETA DEFENSIN 3, HUMAN; BETA-DEFENSIN 3, HUMAN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETIC WOUND INFECTION; DRUG EFFICACY; EPITHELIZATION; GENE EXPRESSION; GENE FUNCTION; HUMAN; IN VITRO STUDY; KERATINOCYTE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; SWINE; VIRAL GENE DELIVERY SYSTEM; WOUND CLOSURE; WOUND CONTRACTION; WOUND HEALING; WOUND INFECTION; ADENOVIRUS; ANIMAL; CELL CULTURE; CYTOLOGY; DIABETES MELLITUS; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; METABOLISM; MICROBIOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; STAPHYLOCOCCAL SKIN INFECTION; TRANSGENE;

ANIMALIA; BACTERIA (MICROORGANISMS); STAPHYLOCOCCUS AUREUS; SUIDAE;

ADENOVIRIDAE; ANIMALS; BETA-DEFENSINS; CELLS, CULTURED; DIABETES COMPLICATIONS; DIABETES MELLITUS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; KERATINOCYTES; NEOVASCULARIZATION, PHYSIOLOGIC; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; SWINE; TRANSGENES; WOUND HEALING; WOUND INFECTION;

EID: 65349178179     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1287     Document Type: Article

References (53)

1. ADA. 2006; ADA Complications of diabetes in the United States. http://www.diabetes.org/diabetes-statistics/complications.jsp.
2. Apelqvist J, Larsson J. What is the most effective way to reduce incidence of amputation in the diabetic foot? Diabetes Metab Res Rev 2000; 16(Suppl 1): S75-S83.
3. Jude EB, Abbott CA, Young MJ, et al. The potential role of cell adhesion molecules in the pathogenesis of diabetic neuropathy. Diabetologia 1998; 41: 330-336.
4. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet 2003; 361: 1545-1551.
5. Ferguson MW, Herrick SE, Spencer MJ, et al. The histology of diabetic foot ulcers. Diabet Med 1996; 13(Suppl 1): S30-S33.
6. Delamaire M, Maugendre D, Moreno M, et al. Impaired leucocyte functions in diabetic patients. Diabet Med 1997; 14: 29-34.
7. Wysocki J, Wierusz-Wysocka B, Wykretowicz A, et al. The influence of thymus extracts on the chemotaxis of polymorphonuclear neutrophils (PMN) from patients with insulin-dependent diabetes mellitus (IDD). Thymus 1992; 20: 63-67.
8. Goldstein EJ, Citron DM, Nesbit CA. Diabetic foot infections. Bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases. Diabetes Care 1996; 19: 638-641.
9. Steinstraesser L, Tack BF, Waring AJ, et al. Activity of novispirin G10 against Pseudomonas aeruginosa in vitro and in infected burns. Antimicrob Agents Chemother 2002; 46: 1837-1844.
10. Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32(Suppl 2): S114-S132.
11. Clark NC, Weigel LM, Patel JB, et al. Comparison of Tn1546-like elements in vancomycin-resistant Staphylococcus aureus isolates from Michigan and Pennsylvania. Antimicrob Agents Chemother 2005; 49: 470-472.
12. Ganz T, Lehrer RI. Antibiotic peptides from higher eukaryotes: biology and applications. Mol Med Today 1999; 5: 292-297.
13. Lehrer RI, Ganz T. Antimicrobial peptides in mammalian and insect host defence. Curr Opin Immunol 1999; 11: 23-27.
14. Hirsch T, Jacobsen F, Steinau HU, et al. Host defense peptides and the new line of defence against multiresistant infections. Protein Pept Lett 2008; 15: 238-243.
15. Fulton C, Anderson GM, Zasloff M, et al. Expression of natural peptide antibiotics in human skin. Lancet 1997; 350: 1750-1751.
16. Ali RS, Falconer A, Ikram M, et al. Expression of the peptide antibiotics human beta defensin-1 and human beta defensin-2 in normal human skin. J Invest Dermatol 2001; 117: 106-111.
17. Niyonsaba F, Ogawa H. Protective roles of the skin against infection: implication of naturally occurring human antimicrobial agents beta-defensins, cathelicidin LL-37 and lysozyme. J Dermatol Sci 2005; 40: 157-168.
18. Harder J, Bartels J, Christophers E, et al. A peptide antibiotic from human skin. Nature 1997; 387: 861.
19. Harder J, Bartels J, Christophers E, et al. Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 2001; 276: 5707-5713.
20. Harder J, Meyer-Hoffert U, Wehkamp K, et al. Differential gene induction of human beta-defensins (hBD-1, -2, -3, and -4) in keratinocytes is inhibited by retinoic acid. J Invest Dermatol 2004; 123: 522-529.
21. Ali MF, Soto A, Knoop FC, et al. Antimicrobial peptides isolated from skin secretions of the diploid frog, Xenopus tropicalis (Pipidae). Biochim Biophys Acta 2001; 1550: 81-89.
22. Oppenheim JJ, Biragyn A, Kwak LW, et al. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann Rheum Dis 2003; 62(Suppl 2): II17-II 21.
23. Garcia JR, Jaumann F, Schulz S, et al. Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res 2001; 306: 257-264.
24. Jia HP, Schutte BC, Schudy A, et al. Discovery of new human beta-defensins using a genomics-based approach. Gene 2001; 263: 211-218.
25. Maisetta G, Batoni G, Esin S, et al. In vitro bactericidal activity of human β-defensin 3 against multidrug-resistant nosocomial strains. Antimicrob Agents Chemother 2006; 50: 806-809.
26. Steinberg DA, Hurst MA, Fujii CA, et al. Protegrin-1: a broad-spectrum, rapidly microbicidal peptide with in vivo activity. Antimicrob Agents Chemother 1997; 41: 1738-1742.
27. Sorensen OE, Thapa DR, Roupe KM, et al. Injury-induced innate immune response in human skin mediated by transactivation of the epidermal growth factor receptor. J Clin Invest 2006; 116: 1878-1885.
28. Hirsch T, Metzig M, Niederbichler A, et al. Role of host defense peptides of the innate immune response in sepsis. Shock 2008; 30: 117-126.
29. Befus AD, Mowat C, Gilchrist M, et al. Neutrophil defensins induce histamine secretion from mast cells: mechanisms of action. J Immunol 1999; 163: 947-953.
30. Chen X, Niyonsaba F, Ushio H, et al. Antimicrobial peptides human beta-defensin (hBD)-3 and hBD-4 activate mast cells and increase skin vascular permeability. Eur J Immunol 2007; 37: 434-444.
31. Niyonsaba F, Ushio H, Nakano N, et al. Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J Invest Dermatol 2007; 127: 594-604.
32. Velander P, Theopold C, Hirsch T, et al. Impaired wound healing in an acute diabetic pig model and the effects of local hyperglycemia. Wound Repair Regen 2008; 16: 288-293.
33. Hirsch T, Spielmann M, Zuhaili B, et al. Enhanced susceptibility to infections in a diabetic wound healing model. BMC Surg 2008; 8: 5.
34. Hirsch T, Spielmann M, Velander P, et al. Insulin-like growth factor-1 gene therapy and cell transplantation in diabetic wounds. J Gene Med 2008; 10: 1247-1252.
35. Eriksson E, Yao F, Svensjo T, et al. In vivo gene transfer to skin and wound by microseeding. J Surg Res 1998; 78: 85-91.
36. Graham FL, Prevec L. Methods for construction of adenovirus vectors. Mol Biotechnol 1995; 3: 207-220.
37. Hirsch T, von Peter S, Dubin G, et al. Adenoviral gene delivery to primary human cutaneous cells and burn wounds. Mol Med 2006; 12: 199-207.
38. Breuing K, Kaplan S, Liu P, et al. Wound fluid bacterial levels exceed tissue bacterial counts in controlled porcine partial-thickness burn infections. Plast Reconstr Surg 2003; 111: 781-788.
39. Onderdonk AB, Dvorak AM, Cisneros RL, et al. Microbiologic assessment of tissue biopsy samples from ileal pouch patients. J Clin Microbiol 1992; 30: 312-317.
40. O'Meara S, Nelson EA, Golder S, et al. Systematic review of methods to diagnose infection in foot ulcers in diabetes. Diabet Med 2006; 23: 341-347.
41. Wu Z, Hoover DM, Yang D, et al. Engineering disulfide bridges to dissect antimicrobial and chemotactic activities of human beta-defensin 3. Proc Natl Acad Sci USA 2003; 100: 8880-8885.
42. Hoover DM, Boulegue C, Yang D, et al. The structure of human macrophage inflammatory protein-3alpha/CCL20. Linking antimicrobial and CC chemokine receptor-6-binding activities with human beta-defensins. J Biol Chem 2002; 277: 37647-37654.
43. Bohling A, Hagge SO, Roes S, et al. Lipid-specific membrane activity of human beta-defensin-3. Biochemistry 2006; 45: 5663-5670.
44. Brown KL, Hancock RE. Cationic host defense (antimicrobial) peptides. Curr Opin Immunol 2006; 18: 24-30.
45. Dunsche A, Acil Y, Dommisch H, et al. The novel human beta-defensin-3 is widely expressed in oral tissues. Eur J Oral Sci 2002; 110: 121-124.
46. Baranska-Rybak W, Sonesson A, Nowicki R, et al. Glycosamino-glycans inhibit the antibacterial activity of LL-37 in biological fluids. J Antimicrob Chemother 2006; 57: 260-265.
47. Weiner DJ, Bucki R, Janmey PA. The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin. Am J Respir Cell Mol Biol 2003; 28: 738-745.
48. Sang Y, Patil AA, Zhang G, et al. Bioinformatic and expression analysis of novel porcine beta-defensins. Mamm Genome 2006; 17: 332-339.
49. Rees RH, Hirshberg JA. Wound care centers: costs, care and strategies. Adv Wound Care 1999; 12: 4-7.
50. Zhang L, Falla TJ. Antimicrobial peptides: therapeutic potential. Expert Opin Pharmacother 2006; 7: 653-663.
51. Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nature Biotechnol 2006; 24: 1551-1557.
52. Kisich KO, Howell MD, Boguniewicz M, et al. The constitutive capacity of human keratinocytes to kill Staphylococcus aureus is dependent on beta-defensin 3. J Invest Dermatol 2007; 127: 2368-2380.
53. Schroder JM, Harder J. Antimicrobial skin peptides and proteins. Cell Mol Life Sci 2006; 63: 469-486.